SCCYF - Scythian Biosciences Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
3.31
+0.11 (+3.44%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close3.20
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume181,115
Market Cap162.067M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) applauds the United Kingdom’s decision to allow specialist doctors the option to legally issue prescriptions for cannabis-based medicines when they believe patients could benefit from the treatment. The law change, passed in Parliament yesterday, came after Home Secretary Sajid Javid listened to concerns from parents of children with conditions such as severe epilepsy.

  • GlobeNewswire7 days ago

    Scythian Biosciences Announces Major Milestone in U.S. Expansion

    Chris, Formerly with Incredibles, One of the Industry’s Leading Vape, Extracts and Wellness Companies, Has Nearly Two Decades of Experience in Greenhouse Architecture, Management and Cultivation. TORONTO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced the  Florida Department of Health, Office of Medical Marijuana Use (“DOH”) has approved the transfer of 60% of the Equity of 3 Boys Farms, LLC. (“3 Boys Farms”) to CannCure Investments Inc. (“CannCure”) including 3 Boys Farms’ license to operate as a Medical Marijuana Treatment Center in Florida.

  • GlobeNewswire17 days ago

    Scythian Biosciences Announces Intention to Commence Normal Course Issuer Bid to Repurchase up to 5% of its Common Shares

    Scythian Biosciences Corp. (“Scythian” or the “Company”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) announced its intention to commence a normal course issuer bid (“NCIB”), under which the Company may purchase up to 2,451,861 of the Company’s common shares, representing approximately 5% of its issued and outstanding common shares (the “Shares”). The Company is commencing the NCIB because it believes that, from time to time, the market price of its Shares may not fully reflect the underlying value of the Company’s business and future prospects.

  • GlobeNewswire20 days ago

    Scythian Biosciences Appoints Peter Liabotis as CFO

    Peter Liabotis, a veteran senior corporate finance executive and certified public accountant, has been appointed Chief Financial Officer of Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF), a company that invests in leading cultivation, distribution and retail operators in the U.S. cannabis industry. “Peter brings expertise in complex financial issues to Scythian as we embark on building out a portfolio of blue-chip cannabis companies across the United States,” Scythian CEO Rob Reid said. Prior to joining Scythian, Mr. Liabotis was Chief Financial Officer of a publicly-traded Toronto merchant bank which invested in equity, debt and convertible debt in early and growth-stage public and private companies.

  • GlobeNewswire21 days ago

    Scythian Biosciences Closes Strategic Sale of Latin American and Caribbean Assets

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) has closed its strategic sale of the Company’s Latin American and Caribbean assets to Aphria Inc. (APH.TO) (“Aphria”), a leading global cannabis company. This sale will provide Scythian with leverage for early stage investments in emerging U.S. markets.

  • GlobeNewswire27 days ago

    Scythian Biosciences Closes Acquisition of MMJ International Investments Inc.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) has completed its acquisition of MMJ International Investments Inc. (“MMJ International”), a privately-held British Columbia company that owns 100% of ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina (the “Acquisition”).

  • GlobeNewswirelast month

    Scythian Biosciences Announces Successful Results of Special Meeting of Shareholders

    Shareholders Approve Name Change to SOL Investments Corp. TORONTO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) is pleased to announce the results of Scythian’s special meeting of shareholders on September 14, 2018 (“Special Meeting”).

  • GlobeNewswirelast month

    Scythian Biosciences Announces Execution of Share Purchase Agreement with MMJ International Investments Inc., owner of Argentina-based ABP S.A.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) announces that it has entered into a definitive share purchase agreement (the “Purchase Agreement”) with MMJ International Investments Inc. (“MMJ”), a privately-held British Columbia company and all of the shareholders of MMJ, to acquire all of the issued and outstanding common shares of MMJ (the “Acquisition”).  MMJ is the owner of Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina. ABP also holds a license to import cannabidiol oil into Argentina. The Purchase Agreement supersedes the previously-announced business combination agreement between Scythian and MMJ to effect the Acquisition.

  • GlobeNewswirelast month

    Scythian Biosciences Closes Acquisition of Marigold Projects Jamaica

    Closing Is Key Benchmark in Finalizing Previously Announced $193 Million Sale of Assets in Caribbean and Latin America. Shares to Be Received in Consideration for the Proposed Sale of Assets in Caribbean ...

  • GlobeNewswire2 months ago

    Scythian Biosciences Closes Acquisition of MMJ Colombia Partners

    TORONTO, Aug. 27, 2018-- Scythian Biosciences Corp. has completed its acquisition of MMJ Colombia Partners Inc., a privately-held Ontario company that owns 90% of Colcanna SAS, a company that cultivates, ...

  • GlobeNewswire2 months ago

    Scythian Biosciences Shifts Focus Exclusively to The United States as National Acceptance of Medical Cannabis Surges

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) has announced that its strategic focus will shift towards the burgeoning U.S. medical cannabis marketplace. Medical cannabis is currently legal in 29 U.S. States, and several key reform bills are moving through the United States Congress, including the STATES ACT (which would remove cannabis from Schedule 1 of the Controlled Substances Act in states where it is legal), the HEMP Farming Act (which would remove CBD products from Schedule 1 of the Controlled Substances Act), and several key banking and tax reform bills.

  • Newsfile2 months ago

    CSE New Listing - Scythian Biosciences Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - August 16, 2018) - Scythian Biosciences Corp. (CSE: SCYB) (FSE: 9SB) (OTCQB: SCCYF) is the latest new listing on the Canadian Securities Exchange, having previously traded on the TSX Venture Exchange. Scythian is an international cannabis company with a focus on the world's leading markets outside of Canada.Cannot view this video? Visit:http://www.investmentpitch.com/video/0_iqfkmq3h/Scythian-Biosciences-Corp-CSESCYB-New-ListingInvestmentPitch Media has produced a "video" which provides a brief overview of the company. If this link ...

  • GlobeNewswire2 months ago

    Scythian Biosciences to Commence Trading on the Canadian Securities Exchange

    Shares of Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) is pleased to announce that it will commence trading on the Canadian Securities Exchange (the "CSE") under the symbol "SCYB" beginning when the market opens on Wednesday August 15, 2018. “The TSX Venture Exchange policies required that we delist from the exchange prior to completion of any acquisitions of United States based cannabis companies. With our strategic expansion into the United States, it was determined best to delist from the TSX Venture Exchange at this point in time.

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Licencing of Colcanna SAS to Cultivate and Import THC into Colombia

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl: SCCYF)  is pleased to announce that Colombian-based Colcanna SAS (“Colcanna”), has received a licence for the cultivation and importation of Tetrahydrocannabinol (“THC”) by the Ministry of Justice and Law of Colombia. With this additional licence, Colcanna is now authorized to cultivate, import, extract and produce THC, as well as cannabidiol – two of the main constituents of cannabis. Additionally, MMJ Colombia Partners, a privately-held Ontario company, has completed its acquisition of 90% of Colcanna SAS.

  • GlobeNewswire3 months ago

    Scythian Invests in PRØHBTD, a Leading Global Cannabis Media Platform

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl: SCCYF) today announced it has invested in and entered into a strategic partnership with PRØHBTD Media, Inc, a leading global cannabis media and brand platform. PRØHBTD has built a first-of-its-kind cannabis ecosystem that includes a brand creation and product development platform, complemented by an original content studio and the first and largest multi-platform video network in the cannabis industry. In addition to the company’s flagship lifestyle destination www.prohbtd.com, video content is syndicated across 15 different partner platforms, including Apple TV, Roku, Amazon, Android TV, Dailymotion and others, which saw more than 22 million video views in June, with an average view-through rate of 3:47 minutes.

  • GlobeNewswire3 months ago

    Scythian Biosciences to Acquire Company with Exclusive Medical Cannabis License in Florida

    Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced it has signed an arm’s length letter of intent effective July 26, 2018 to acquire CannCure Investments Inc. (“CannCure”).

  • GlobeNewswire3 months ago

    Scythian Biosciences Announces Director Resignation

    Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced that Mr. George Scorsis has resigned from its board of directors, and that Rob Reid has been appointed Interim Chairman. George Scorsis said: “It’s been a great pleasure to help guide Scythian on its journey to becoming the global cannabis player it is today, and I have no doubt the company will continue to make great strides in its research and expansion efforts.

  • GlobeNewswire3 months ago

    Scythian Chief Medical Officer Professor Michael Barnes Expands Global Influence as a Cannabis Key Opinion Leader

    Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced that its Chief Medical Officer, Professor Michael Barnes, is rapidly expanding his international strategy and influential reach. Professor Barnes, MD, FRCP, is a leading world authority in neurological rehabilitation and has emerged as an influential voice in medical cannabis policy in Europe.

  • GlobeNewswire3 months ago

    Scythian Biosciences Corp. Announces Strategic Partnership for Cannabis in Brazil with one of the Founders of the Country’s Pharma Industry

    Scythian Biosciences Corp. (to be renamed Sol Global Investments Corp.) (the "Company" or “Scythian”) (SCYB.V) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is thrilled to announce its Brazilian partnership with Green Farma Brasil of Sao Paulo. The partnership will be managed by Brazilian Pharmaceutical veteran, Adalmiro Dellape Baptista Junior (“Adalmiro”), the son of Aché Pharmaceutical Laboratories (“Group Aché”) founder, Brazil’s third largest pharmaceutical companies.  Adalmiro has devoted more than 30 years of his life to the pharmaceutical industry and has experience in all areas of the Brazilian market.

  • The Global Cannabis Market Is Set To Explode
    Oilprice.com3 months ago

    The Global Cannabis Market Is Set To Explode

    2018 saw the North American cannabis market explode, peaking when Canada announced it will fully legalize recreational use, but the opportunities for this commodity are only just beginning